Sino Biopharmaceutical's first-half 2026 revenue grew 11% year on year to CNY 19.4 billion, while operating margin increased 1,300 basis points, mainly driven by out-licensing agreements made with Sanofi earlier this year.
Anxu could become a blockbuster drug, which would lead to upward revisions for Sino Biopharm's growth outlook.
Price cuts from VBP could continue to pressure pricing of Sino Bio’s drugs more than expected and lead to a weaker revenue outlook and margin performance.
|
Metric
|
01177
|
01801
|
06160
|
|---|---|---|---|
Price/Earnings (Normalized) | 40.68 | 99.29 | 44.84 |
Price/Book Value | 2.71 | 7.79 | 8.17 |
Price/Sales | 2.74 | 9.98 | 7.06 |
Price/Cash Flow | 8.84 | 68.32 | 32.31 |
|
Metric
|
01177
|
01801
|
06160
|
|---|---|---|---|
Quick Ratio | 1.56 | 2.48 | 2.91 |
Current Ratio | 1.63 | 2.68 | 3.40 |
Interest Coverage | 23.97 | 17.01 | 62.41 |
|
Metric
|
01177
|
01801
|
06160
|
|---|---|---|---|
Return on Assets (Normalized) | 6.14% | 6.48% | 16.92% |
Return on Equity (Normalized) | 14.88% | 13.49% | 30.37% |
Return on Invested Capital (Normalized) | 7.21% | 8.48% | 24.59% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|j?xNn?z | LOCK|Y^t> | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|d?Lz!V | LOCK|<V#@! | $76B | |||
| Moderna Inc
MRNA
| LOCK|?w^&Pz | LOCK|#? | $75B | |||
| argenx SE ADR
ARGX
| LOCK|rYfJ^#! | LOCK|TN | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|qRkxzH | LOCK|Sb | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|M?%$bJ | LOCK|BHvz | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^LyD@>L | LOCK|<Qd?K | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|r^!%>^ | LOCK|>zJ | $24B | |||
| Incyte Corp
INCY
| LOCK|vn$>?Fq | LOCK|bcF | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?d@lyn | LOCK|ZzQ | $15B |
United States